>> In the market segment of genetically engineered drugs, 114 active ingredients are currently approved (see vfa, as of June 6, 2014, although biosimilars with the same name are not counted as new active ingredients here, unlike the vfa). There are only biosimilars from different providers on the market for five of these 114 active ingredients. The analysis looks at the three top-selling active ingredients or active ingredient groups: biosimilar epoetins (epoetin alfa and zeta), filgrastim and somatropin. For the latter two biopharmaceuticals filgrastim and somatropin, further copycat products were approved in 2013, after there had been no biosimilar approvals at all in 2011 and 2012 (see vfa, “Medical Biotechnology in Germany 2014”).
In addition to the three active ingredients/groups of active ingredients already mentioned, biosimilars for follitropin alfa and infliximab are approved.

...

Subscribe to print magazine

Order individual issue

Citation information: doi: 10.24945/MVF.04.14.1866-0533.1949